Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
A Phase II Study of Duvelisib Plus Docetaxel in PD-1 Inhibitor Experienced Patients With Incurable Head and Neck Squamous Cell Carcinoma
Sponsor: Glenn J. Hanna
This PHASE2 trial investigates Advanced Head and Neck Cancer and Advanced Head and Neck Squamous Cell Carcinoma and is currently completed. Glenn J. Hanna leads this study, which shows 11 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Mar 2022 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Glenn J. Hanna
- Secura Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .